Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 33, Issue 2, 2017, Pages 359-369

  Shao, Hui ^a   Zhai, Suodi ^b   Zou, Dajin ^c   Mir, Mohammed Umer ^a   Zawadzki, Nadine K ^a   Shi, Qian ^a   Liu, Shuqian ^a   Shi, Lizheng ^a  

^a TULANE UNIVERSITY   (United States)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cost effectiveness; dapagliflozin; glimepiride; monotherapy; type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; DAPAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIFF MODEL; CHINA; CHINESE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC MODEL; GENITAL TRACT INFECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT GAIN; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FEMALE; HEALTH CARE COST;

BENZHYDRYL COMPOUNDS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS;

EID: 84996841828     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1257978     Document Type: Article

References (78)

1. Zuo H, Shi Z, Hussain A., Prevalence, trends and risk factors for the diabetes epidemic in China:a systematic review and meta-analysis. Diabetes Res Clin Pract 2014;104:63-72
2. Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 1997;20:1664-9
3. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
4. WHO. Noncommunicable Disease (NCD) Country Profile China 2014. 2014. Available at:http://www.who.int/nmh/countries/chn_en.pdf April 2, 2016
5. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010:findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987-2015
6. Wang W, McGreevey WP, Fu C. Type 2 diabetes mellitus in China:a preventable economic burden. Am J Manag Care 2009;15:593-601
7. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2224-60
8. Lane S, Levy AR, Mukherjee J. Overweight and obesity (high body mass index). Comparative quantification of health risks:global and regional burden of disease attribution to selected major risk factors 2004;1:497-596
9. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59
10. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
11. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin:a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Medicinal Chemistry 2008;51:1145-9
12. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82
13. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investigation 1994;93:397
14. Fonseca VA., Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(Suppl2):S151-S6
15. Gerich J., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus:therapeutic implications. Diabetic Med 2010;27:136-42
16. Whaley JM, Tirmenstein MR, Timothy P, et al. Targeting the kidney and glucose excretion with dapagliflozin:preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012;5:135-48
17. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
18. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metabol 2011;97:1020-31
19. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metabol 2014;16:159-69
20. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride:a randomized, 24‐week, double‐blind, placebo‐controlled trial. Diabetes Obes Metabol 2011;13:928-38
21. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62
22. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin:a randomized trial. Ann Intern Med 2012;156:405-15
23. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin:efficacy and safety over 2 years. Diabetes Obes Metabol 2014;16:124-36
24. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control:a phase II multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metabol 2013;15:432-40
25. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metabol 2014;16:1102-10
26. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
27. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both:initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56
28. List JF, Woo V, Morales E, et al. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
29. Rosenstock J, Vico M, Wei LI, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
30. Nauck M, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
31. Aylsworth A. Dean Z, VanNorman C. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50
32. Yang L, Li H, Li H. Pharmacokinetic and pharmacodynamic properties of single-and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Therapeut 2013;35:1211-22.e2
33. Ji L, Lu J, Weng J, et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. Journal of diabetes, 7, 166-173
34. Massi-Benedetti M., Glimerpiride in type 2 diabetes mellitus:a review of the worldwide therapeutic experience. Clin Therapeut 2003;25:799-816
35. Langtly H, Balfour JA., Glimepiride, a review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84
36. Campbell RK., Glimepiride:role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52
37. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM:II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
38. Mount H., Computer modeling of diabetes and its complications:a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638
39. Palmer AJ., Roze S, Valentine WJ. Computer modeling of diabetes and its complications:a report on the fifth Mount Hood challenge meeting. Value Health 2013;16:670-85
40. Deng J, Gu S, Shao H, et al. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies. J Med Econ 2015;18:974-89
41. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
42. China Minister of Health. Chinese Health Statistics Yearbook. Beijing, 2013
43. World Health Organization. The world health report 2002–Chapter 5 (some strategies to reduce risk–technical considerations for cost-effectiveness analysis). 2002. Available at:http://www.who.int/whr/2002/en/Chapter5.pdf?ua¼1 [Last accessed 16 August 2015]
44. Ji L, Ma JH, Li HM, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus:a randomized, blinded, prospective phase III study. Clin Therapeut 2014;36:84-100.e9
45. Bautista JL, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus:a randomized, placebo-controlled study. Clin Therapeut 2003;25:194-209
46. Goldberg RB, Holvey SM, Schneider J, et al. A dose–response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-56
47. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42
48. Nandy D, Johnson C, Basu R, et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diabetes Vas Dis Res 2014;11:419-30
49. Cefalu WT, Leiter LA, Debruin TW, et al. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension. Diabetes 2012;61(Suppl1):A271
50. Hoepelman AI, Meiland R, Geerlings SE., Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003;22:35-43
51. Mitri J, Hamdy O., Diabetes medications and body weight. Expert Opin Drug Saf 2009;8:573-84
52. Nauck M, Del P, Meier S, et al. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Deutsche Medizinische Wochenschrift (1946) 2013;138:S6-S15
53. Price Bureau of China Official drug price list. 2014. Available at:http://www.zjpi.gov.cn/main/html/2013/CT10138/75fbbde9c06b496aba6490646b9ca77f.html April 2, 2016
54. Gao L, Zhao F-L, Li S-C., Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;28:436-44
55. Zheng Y, Wu J, Xie K., Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Admin 2012;32:1195-8
56. Meng H., Pharmacoeconomic analysis of the treatment of type 2 diabetes complicated with urinary infections with two different antibiotics. J Shandong Med College 2009;31:91-3
57. Worldwide Inflation Data. Historic inflation China. Available at:http://www.inflation.eu/inflation-rates/china/historic-inflation/cpi-inflation-china.aspx [Last accessed 3 August 2016]
58. Guo H, Li J, Jiang Z., Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. Chinese J Rehab Med 2007;22:395-8
59. Clarke P, Gray A, Holman R., Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decision Making 2002;22:340-9
60. Currie CJ, Morgan C, Li P, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
61. Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
62. Barry HC, Ebell MH, Hickner J., Evaluation of suspected urinary tract infection in ambulatory women:a cost–utility analysis of office-based strategies. J Urol 1998;159:1418-19
63. China GDP., 2014. Available at:http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj =2014 April 2, 2016
64. Wilding JP, Woo V, Soler NG, et al. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]. Deutsche Medizinische Wochenschrift (1946) 2013;138:S27-S38
65. Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
66. Vivian EM., Dapagliflozin:a new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm 2015;72:361-72
67. Abdul-Ghani MA, Merovci A, Solis-Herrera C, et al. Plasma glucose reduction with the SGLT2 inhibitor, dapagliflozin, improves insulin sensitivity and insulin secretion in T2DM. In:Diabetes. Alexandria, VA, USA:American Diabetes Association, 2013
68. Robinson KA, Dickersin K., Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150-3
69. Biondi-Zoccai G, Agostoni P, Abbat A, et al. A simple hint to improve Robinson and Dickersin’s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005;34:224-5; author reply 225
70. Sterne JA, Bradburn MJ, Egger M., Meta-Analysis in Stata. Systematic Reviews in Health Care:Meta-Analysis in Context, 2nd edn. BMJ Books, 2008:347-69
71. Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013;126:925.e11-22
72. Li H, Xu F, Wang F., Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese J New Drugs 2011;20:2163-70
73. Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752-74
74. Zheng Y, Wu J, Xie K., Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus. Chinese Rural Health Servic Administration 2012:1195-8
75. Craig CJ, Phil M, John P, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR):descriptive analysis from the first 20,000 subjects. Value in Health 2005;8:581-90
76. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality Life Res 2007;16:1251-65
77. Currie CJ, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
78. Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk:estimates from a Markov model. J Med Econ 2007;10:239-54